AU4772299A - Fas peptides and antibodies for modulating apoptosis - Google Patents

Fas peptides and antibodies for modulating apoptosis

Info

Publication number
AU4772299A
AU4772299A AU47722/99A AU4772299A AU4772299A AU 4772299 A AU4772299 A AU 4772299A AU 47722/99 A AU47722/99 A AU 47722/99A AU 4772299 A AU4772299 A AU 4772299A AU 4772299 A AU4772299 A AU 4772299A
Authority
AU
Australia
Prior art keywords
antibodies
fas
peptides
modulating apoptosis
cellular proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU47722/99A
Other languages
English (en)
Inventor
Francesca Chiodi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karolinska Innovations AB
Original Assignee
Karolinska Innovations AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9813194.9A external-priority patent/GB9813194D0/en
Priority claimed from GBGB9905793.7A external-priority patent/GB9905793D0/en
Application filed by Karolinska Innovations AB filed Critical Karolinska Innovations AB
Publication of AU4772299A publication Critical patent/AU4772299A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU47722/99A 1998-06-18 1999-06-15 Fas peptides and antibodies for modulating apoptosis Abandoned AU4772299A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9813194.9A GB9813194D0 (en) 1998-06-18 1998-06-18 Methods and means for modulating apoptosis
GB9813194 1998-06-18
GBGB9905793.7A GB9905793D0 (en) 1998-06-18 1999-03-12 Methods and means for modulating apoptosis
GB9905793 1999-03-12
PCT/EP1999/004105 WO1999065935A2 (en) 1998-06-18 1999-06-15 Fas peptides and antibodies for modulating apoptosis

Publications (1)

Publication Number Publication Date
AU4772299A true AU4772299A (en) 2000-01-05

Family

ID=26313898

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47722/99A Abandoned AU4772299A (en) 1998-06-18 1999-06-15 Fas peptides and antibodies for modulating apoptosis

Country Status (9)

Country Link
US (1) US6846637B1 (de)
EP (1) EP1087993B1 (de)
AT (1) ATE391136T1 (de)
AU (1) AU4772299A (de)
DE (1) DE69938451T2 (de)
DK (1) DK1087993T3 (de)
ES (1) ES2306515T3 (de)
PT (1) PT1087993E (de)
WO (1) WO1999065935A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2490542C (en) * 2002-05-23 2013-07-16 Mark I. Greene Fas peptide mimetics and uses thereof
EP1521776A2 (de) 2002-07-04 2005-04-13 Oncomab Gmbh Neoplasma-spezifische antikörper und deren verwendungen
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
EP1620564A4 (de) * 2003-04-18 2008-03-12 Cytovia Inc Verfahren zur behandlung von auf apoptoseinduktion reagierenden krankheiten und screening-tests
EP1742969A2 (de) * 2003-11-12 2007-01-17 OncoMab GmbH Verfahren zur identifizierung neoplasmaspezifischer antikörper und verwendungen davon
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (de) 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
US7759077B2 (en) 2005-08-02 2010-07-20 Shariat Shahrokh F Soluble fas urinary marker for the detection of bladder transitional cell carcinoma
SI2428252T1 (sl) 2006-12-28 2015-01-30 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Nevtralizacija invazije aktivnostnih blokov cd95 v celicah glioblastoma in vivo
WO2010006772A2 (en) * 2008-07-14 2010-01-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
US20100233157A1 (en) * 2009-03-12 2010-09-16 Osorio Lyda M Human antibodies against human fas and their use
CN104640568B (zh) 2012-07-18 2016-10-19 阿珀吉尼科斯股份公司 用于治疗mds的cd95信号传导途径的抑制剂
WO2014186877A1 (en) 2013-05-24 2014-11-27 Uger Marni Diane FasR ANTIBODIES FOR DIAGNOSTIC AND THERAPEUTIC USE
EP2898896A1 (de) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Mittel zur Verwendung bei der Behandlung von Netzhautentzündung
ES2796857T3 (es) * 2014-04-17 2020-11-30 Inst Nat Sante Rech Med Polipéptidos y usos de los mismos para reducir la motilidad celular mediada por CD95
EP3076179A1 (de) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnose und behandlung von minderwertigen glioma
CA3023802C (en) 2016-05-10 2025-02-04 Inserm (Institut De La Sante Et De La Recherche Medicale) ACTIVATING AGENTS OF THE DIFFERENTIATION CLUSTER 47 FOR USE IN THE TREATMENT OF INFLAMMATION
US20220177841A1 (en) 2019-03-29 2022-06-09 Myst Therapeutics Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
US20230032934A1 (en) 2019-11-27 2023-02-02 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
EP4512828A3 (de) 2020-02-27 2025-05-14 Turnstone Biologics Corp. Verfahren zur ex-vivo-anreicherung und vermehrung von tumorreaktiven t-zellen und verwandten zusammensetzungen davon
WO2026044087A1 (en) 2024-08-21 2026-02-26 Shape Therapeutics Inc. Increased cellular stability for aav production
WO2026073032A1 (en) 2024-09-27 2026-04-02 Shape Therapeutics Inc. Constructs for improved aav production

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0511202B1 (de) 1990-01-19 1994-06-01 German Cancer Research Center Mit zellularer apoptosis assoziiertes zelloberflächenantigen
CA2067031C (en) 1991-04-26 2003-02-18 Shigekazu Nagata Dna coding for human cell surface antigen
US5891434A (en) 1991-06-17 1999-04-06 Centocor, Inc. Monoclonal antibodies to the APO-1 antigen
WO1995010540A1 (en) 1993-10-14 1995-04-20 Immunex Corporation Fas antagonists and uses thereof
US5830469A (en) 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
US5663070A (en) * 1993-11-15 1997-09-02 Lxr Biotechnology Inc. Recombinant production of a soluble splice variant of the Fas (Apo-1) antigen, fas TM
CA2158822C (en) 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
JPH08157500A (ja) * 1994-12-08 1996-06-18 Oriental Yeast Co Ltd Ｆａｓ抗原の定量法
WO1997012632A1 (en) 1995-10-05 1997-04-10 Tkb Associates Limited Partnership Methods for treatment of diseases associated with a deficiency of fas ligand activity
DE19544332C2 (de) * 1995-11-28 1999-07-08 Deutsches Krebsforsch Verfahren zum Nachweis der Expression von CD95 Ligand in Zellen
JP3663243B2 (ja) * 1995-12-14 2005-06-22 株式会社医学生物学研究所 Ｆａｓ抗原の免疫学的測定法及び測定用キット
AU724579B2 (en) 1996-04-01 2000-09-28 Sankyo Company Limited Anti-Fas recombinant antibodies and DNA therefor
US5912168A (en) * 1996-08-30 1999-06-15 Genesis Research & Development Corporation Limited CD95 regulatory gene sequences
IL123756A0 (en) * 1997-03-21 1998-10-30 Sankyo Co Humanized anti-human FAS antibody
IL123888A0 (en) * 1997-04-01 1998-10-30 Sankyo Co Anti-fas antibodies
AU757961B2 (en) 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
MXPA01012206A (es) 1999-05-24 2002-06-21 Sankyo Co Composiciones farmaceuticas que contienen anticuerpo anti-fas.

Also Published As

Publication number Publication date
US6846637B1 (en) 2005-01-25
DK1087993T3 (da) 2008-07-14
WO1999065935A2 (en) 1999-12-23
DE69938451T2 (de) 2009-04-09
DE69938451D1 (de) 2008-05-15
EP1087993A1 (de) 2001-04-04
EP1087993B1 (de) 2008-04-02
ES2306515T3 (es) 2008-11-01
PT1087993E (pt) 2008-07-04
WO1999065935A3 (en) 2003-04-17
ATE391136T1 (de) 2008-04-15

Similar Documents

Publication Publication Date Title
AU4772299A (en) Fas peptides and antibodies for modulating apoptosis
NZ332598A (en) Human BAS-1 protein, and use as an antagonist for modulating physiology or development of a cell
WO2003048337A3 (en) Antibody to latent membrane proteins and uses thereof
AU7301898A (en) Survivin, a protein that inhibits cellular apoptosis, and its modulation
ATE227739T1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
MY157382A (en) Cripto blocking antibodies and uses thereof.
CA2321177A1 (en) Recombinant fibronectin-based extracellular matrix for wound healing
MXPA04002808A (es) Acidos nucleicos receptores de ecdisona de mosca blanca, polipeptidos, y sus usos.
WO2001081415A3 (en) Parathyroid hormone and parathyroid hormone-related protein antagonists
NZ504114A (en) Vitamin k-dependent polypeptides such as protein C where substitution at amino acid sites 11, 12, 29, 33 or 34 affects membrane binding affinity of the protein and ultimately blood clotting ability
WO2004078995A3 (en) Methods of modulating and of identifying agents that modulate intracellular calcium
WO2002078598A3 (en) Peptides and antibodies to muc 1 proteins
AU2002356392A1 (en) Bone polypeptide-1
EP1517144A3 (de) Verfahren zur Identifizierung eines Antikörpers, der einen humanen Vanilloid Rezeptor bindet und dessen Aktivität moduliert
IL134011A0 (en) Adipocyte-specific protein homologs
AU3307999A (en) Phosphodiesterase 10
MXPA02011002A (es) Oligopeptidos para promover el crecimiento del cabello.
WO1999049038A3 (en) Human calcium-binding proteins
AU2169499A (en) Protein humaine beta-trcp
WO1999031128A3 (en) Human tumor necrosis factor-r2-like proteins
WO2000023589A3 (en) Proliferation and apoptosis related proteins
WO1998022500A3 (en) Modulation of interactions between myosin and integrins
BR0207253A (pt) Polinucleotìdeo, polipeptìdeo isolado, anticorpo monoclonal, ou fragmento de ligação do antìgeno do mesmo, vetor de expressão, célula hospedeira, medicamento composição farmacêutica, e, utilização de um polipeptìdio isolado
WO2004096991A3 (en) Bcl2l12 polypeptide activators and inhibitors
WO2000066735A3 (en) Human ion channel proteins

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase